Esophageal cancer is one of the top ten causes of cancerrelated mortality worldwide, with an estimated 572,034 new cases and 508,585 deaths in 2018. 1 In the US, there will be an estimated 17,650 new cases and 16,080 deaths in 2019, making esophageal cancer the seventh leading cause of cancer-related mortality among men. 2 Despite multimodal therapy, the overall 5-year survival for esophageal cancer remains low at 19%. 2 Although surgery remains the only curative treatment, esophagectomy is associated with high perioperative morbidity (40-50%) and mortality (2-8%). 3 Pulmonary complications remain one of the major causes of morbidity and mortality after open esophagectomy (OE). Therefore, minimally invasive approaches, including laparoscopy and/or thoracoscopy, have been used to minimize the impact on pulmonary complications. Total minimally invasive esophagectomy (MIE) involves the use of both laparoscopy and thoracoscopy, whereas hybrid MIE (HMIE) most commonly involves laparoscopic mobilization combined with a thoracotomy. Nagpal et al. conducted a meta-analysis comparing the perioperative outcomes after MIE versus OE, and HMIE versus OE. 4 MIE, when compared with OE, was associated with a significant reduction in blood loss, intensive care unit stay, length of stay, pulmonary complications, and total morbidity (all p \ 0.05). 4 Similarly, HMIE demonstrated a statistically significant association with reduced blood loss, anastomotic leaks, and respiratory complications (all